A Prognostic DNA Methylation Signature for Stage I Non–Small-Cell Lung Cancer

Abstract

The DNA methylation signature of NSCLC affects the outcome of stage I patients, and it can be practically determined by user-friendly polymerase chain reaction assays. The analysis of the best DNA methylation biomarkers improved prognostic accuracy beyond standard staging.